FrancophonIA/ELRC3.0 huggingface dataset:
English: Shelf life of the diluent in polypropylene bottles: 12 months at a temperature below 30°C.
Estonian: Lahusti kõlblikkusaeg polüpropüleen pudelites: 12 kuud temperatuuril alla 30°C.
English: • To prevent mortality and to reduce clinical signs and lesions of Infectious Bursal disease.
Estonian: • Vältimaks suremust ja vähendamaks nakkusliku bursiidi kliinilisi tunnuseid.
English: 1800ml or 2400ml of diluent.
Estonian: 1800ml või 2400 ml lahustiga.
English: Shelf life of the reconstituted vaccine: up to 2 hours at a temperature below 25°C.
Estonian: Manustamiskõlblikuks muudetud vaktsiini säilivusaeg: kuni 2 tundi temperatuuril alla 25°C.
English: • Wear protective gloves and spectacles during the ampoule thawing and opening operations.
Estonian: • Ampulli sulatamise ja avamise ajal kanda kaitsekindaid ja -prille.
English: Store the vaccine in liquid nitrogen.
Estonian: Vaktsiini hoida vedelas lämmastikus.
English: Store the reconstituted vaccine at a temperature below 25°C.
Estonian: Lahustatud vaktsiini hoida temperatuuril alla 25°C.
English: Shelf life of the diluent in polyvinylchloride bags: 36 months at a temperature below 30°C.
Estonian: Lahusti kõlblikkusaeg polüvinüülkloriidkottides: 36 kuud temperatuuril alla 30°C.
English: • Repeat the thawing, opening, transfer and rinsing operations for the appropriate number of ampoules to be reconstituted in the diluent; either 1 ampoule of 1,000 doses of vaccine per 200 ml of diluent (or 1 ampoule of 2,000 doses of vaccine per 400 ml of diluent) for subcutaneous administration, or 4 ampoules of 1,000 doses of vaccine per 200 ml of diluent (or 4 ampoules of 2,000 doses of vaccines per 400 ml of diluent) for in ovo administration.
Estonian: • Korrata sulatamise, avamise, siirdamise ja loputamise operatsioone vajaliku arvu ampullidega, mida peab lahustama; kas siis 1 ampull 1000 vaktsiinidoosiga 200ml lahusti kohta (või 1 ampull 2000 vaktsiinidoosiga 400 ml lahusti kohta) subkutaanseks manustamiseks või 4 ampulli igas 1000 vaktsiinidoosi 200 ml lahusti kohta ( või 4 ampulli, igas 2000 vaktsiinidoosi 400 ml lahusti kohta ) munasse vaktsineerimiseks.
English: Discard any ampoules that have been accidentally thawed.
Estonian: Kogemata sulatatud ampullid hävitada koheselt.
English: Read the package leaflet supplied with the vaccine vial before use.
Estonian: Enne kasutamist lugege vaktsiiniviaaliga kaasasolevat infolehte.
English: In the absence of specific studies, no other veterinary medicinal product should be administered concurrently with the product.
Estonian: Spetsiaaluuringute puudumise tõttu ei tohi munasse vaktsineerimise korral kasutada samaaegselt teisi vaktsiine.
English: Special precautions for use in animals:
Estonian: Erihoiatused kasutamisel loomadel
English: One single injection of 0.05 ml per chicken egg at 18 days of embryonation, by in ovo route.
Estonian: Üks süst 0,05 ml 18-päevaste kanaembrüotega kanamunadele munasse vaktsineerimise korral.
English: Store the diluent below 30°C.
Estonian: Lahusti hoida temperatuuril alla 30°C.
English: Wear protective gloves and spectacles during the ampoule thawing and opening operations.
Estonian: Ampulli sulatamise ja avamise ajal kanda kaitsekindaid ja -prille.
English: Suspension and solvent for suspension for injection
Estonian: Suspensioon ja lahusti süstesuspensiooni valmistamiseks.
English: Laboratory of Lyon Porte des Alpes Rue de l'Aviation, 69800 Saint-Priest France
Estonian: Merial Laboratoire of Lyon Porte des Alpes Rue de l'Aviation,
English: Lay: Do not use in breeding birds and birds in lay.
Estonian: Munemisperiood: Mitte kasutada sugulindudel ja munejatel lindudel.
English: One single injection of 0.2 ml per chicken at the age of one day, by subcutaneous route.
Estonian: Üks süst 0,2 ml ühepäevastele tibudele subkutaanse manustamise korral.
English: PACKAGE LEAFLET FOR: Vaxxitek HVT+IBD suspension and solvent for suspension for injection
Estonian: PAKENDI INFOLEHT Vaxxitek HVT+IBD suspensioon ja lahusti süstesuspensiooni valmistamiseks
English: • Draw up 2 ml of the contents of the diluent into the syringe.
Estonian: • Tõmmata 2 ml lahustit süstlasse.
English: Do not use in breeding birds and birds in lay.
Estonian: Mitte kasutada sugulindudel ja munevatel lindudel.
English: In ovo route: one single injection of 0.05 ml per egg at 18 days of embryonation.
Estonian: Üks süst 0,05 ml 18-päevastele kanaembrüotele munasse vaktsineerimisel.
English: Vaxxitek HVT+IBD Suspension and solvent for suspension for injection
Estonian: Vaxxitek HVT+IBD suspensioon ja lahus süstesuspensiooni valmistamiseks
English: Merial Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest France
Estonian: MERIAL, Laboratoire Porte des Alpes Rue de l'Aviation,
English: For subcutaneous route:
Estonian: Subkutaanselt manustades:
English: Manufacturer responsible for batch release
Estonian: Partii vabastamise eest vastutaja
English: Shelf life of the non-reconstituted vaccine: 36 months at -196°C Shelf life of the reconstituted vaccine: up to 2 hours at a temperature below 25°C.
Estonian: Lahustamata vaktsiini kõlblikkusaeg: 36 kuud temperatuuril -196°C.
English: Chickens
Estonian: Kana.
English: Subcutaneous route: one single injection of 0.2 ml per chicken at the age of one day.
Estonian: Üks süst 0,2 ml ühepäevastele tibudele subkutaansel manustamisel.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE STERILE DILUENT
Estonian: VÄLISPAKENDIL JA SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED {Steriilne lahusti}
English: Dimethyl sulfoxide Dilution medium
Estonian: Dimetüülsulfoksiid Lahustav keskkond
English: 1 bag of 200 ml 1 bag of 400 ml 1 bag of 600 ml.
Estonian: 1 kott 200 ml 1 kott 400 ml 1 kott 600 ml 1 kott 800 ml 1 kott 1000 ml 1 kott 1200 ml 1 kott 1400 ml 1 kott 1600 ml 1 kott 1800 ml 1 kott 2400 ml
English: The full EPAR for Palonosetron Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Palonosetron Accordi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Palonosetron Accord?
Estonian: Mis meetmed võetakse, et tagada Palonosetron Accordi ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Palonosetron Accord is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Palonosetron Accordi võimalikult ohutu kasutamine.
English: Palonosetron Accord palonosetron
Estonian: Palonosetron Accord palonosetroon
English: What is Palonosetron Accord and what is it used for?
Estonian: Mis on Palonosetron Accord ja milleks seda kasutatakse?
English: It is available as a solution for injection or infusion (drip) into a vein, which should be given by a healthcare professional about 30 minutes before the start of chemotherapy.
Estonian: Seda turustatakse süste- või infusioonilahusena, mida peab manustama veeni tervishoiutöötaja ligikaudu 30 minutit enne keemiaravi algust.
English: It is used in adults and children 1 month of age or older for chemotherapy with medicines that are either a strong trigger of nausea and vomiting (such as cisplatin) or a moderate trigger (such as cyclophosphamide, doxorubicin or carboplatin).
Estonian: Seda kasutatakse täiskasvanutel ja vähemalt 1 kuu vanustel lastel kas tugevat (nt tsisplatiin) või mõõdukat iiveldust ja oksendamist põhjustavate keemiaravi ainete (nt tsüklofosfamiid, doksorubitsiin või karboplatiin) korral.
English: The Committee recommended that Palonosetron Accord be approved for use in the EU.
Estonian: Komitee soovitas Palonosetron Accordi kasutamise Euroopa Liidus heaks kiita.
English: Because Palonosetron Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Palonosetron Accord on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: By blocking these receptors, Palonosetron Accord prevents the nausea and vomiting that often happen after chemotherapy.
Estonian: Nende retseptorite blokeerimise abil ennetab Palonosetron Accord iiveldust ja oksendamist, mis sageli esinevad pärast keemiaravi.
English: No additional studies were needed as Palonosetron Accord is a generic medicine that is given by injection and contains the same active substance as the reference medicine, Aloxi.
Estonian: Lisauuringuid ei olnud vaja, sest Palonosetron Accord on süstina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Aloxi.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Palonosetron Accord, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle kava alusel lisati Palonosetron Accordi ravimi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Therefore, the CHMP's view was that, as for Aloxi, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Aloxi korral, ületab ravimi kasulikkus sellega kaasnevaid riske.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Palonosetron Accord has been shown to be comparable to Aloxi.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõestatud ravimi Palonosetron Accord sarnane toime ravimiga Aloxi.
English: This means that it stops a chemical in the body called 5-hydroxytryptamine (5HT, also known as serotonin) from attaching to 5HT3 receptors in the gut.
Estonian: See takistab organismi teatud keemilise aine 5-hüdroksütrüptamiini (5HT ehk serotoniini) seondumist soolestiku 5HT3retseptoritega.
English: It is not intended to provide practical advice on how to use Palonosetron Accord.
Estonian: Hindamisaruandes ei anta Palonosetron Accordi kasutamise praktilisi nõuandeid.
English: This means that Palonosetron Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Aloxi.
Estonian: See tähendab, et Palonosetron Accord on sarnane võrdlusravimiga Aloxi, millel juba on Euroopa Liidus müügiluba.
English: Why is Palonosetron Accord approved?
Estonian: Miks Palonosetron Accord heaks kiideti?
English: For practical information about using Palonosetron Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Palonosetron Accordi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Palonosetron Accord.
Estonian: See on ravimi Palonosetron Accord Euroopa avaliku hindamisaruande kokkuvõte.
English: It may be given with a corticosteroid (another type of medicine that can be used to prevent nausea and vomiting) to increase the effect.
Estonian: Toime suurendamiseks võib ravimit anda koos kortikosteroidiga (teist liiki ravim, mida kasutatakse iivelduse ja oksendamise ennetamiseks).
English: In children, the solution should be given by infusion into a vein over 15 minutes at a dose of 20 micrograms per kilogram body weight.
Estonian: Lastele manustatakse lahust 15-minutilise veeniinfusioonina annuses 20 µg kehamassi kg kohta.
English: Palonosetron Accord should only be given before chemotherapy.
Estonian: Palonosetron Accordi võib manustada ainult enne keemiaravi.
English: The active substance in Palonosetron Accord, palonosetron, is a ‘5HT3 antagonist'.
Estonian: Palonosetron Accordis toimeainena sisalduv palonosetroon on 5HT3 antagonist.
English: Palonosetron Accord is a medicine used to prevent nausea (feeling sick) and vomiting caused by chemotherapy (medicines to treat cancer).
Estonian: Palonosetron Accordi kasutatakse keemiaravi (vähiravimite) põhjustatud iivelduse ja oksendamise ennetamiseks.
English: For more information about treatment with Palonosetron Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Palonosetron Accordiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Palonosetron Accord
Estonian: Muu teave Palonosetron Accordi kohta
English: It is a ‘generic medicine'.
Estonian: Palonosetron Accord on geneeriline ravim.
English: Palonosetron Accord contains the active substance palonosetron.
Estonian: Palonosetron Accord sisaldab toimeainena palonosetrooni.
English: What are the benefits and risks of Palonosetron Accord?
Estonian: Milles seisneb Palonosetron Accordi kasulikkus ja mis riskid ravimiga kaasnevad?
English: How does Palonosetron Accord work?
Estonian: Kuidas Palonosetron Accord toimib?
English: How is Palonosetron Accord used?
Estonian: Kuidas Palonosetron Accordi kasutatakse?
English: How has Palonosetron Accord been studied?
Estonian: Kuidas Palonosetron Accordi uuriti?
English: It may request a retive opinion.
Estonian: Taotleja taotles arvamuse uut läbivaatamist.
English: There was also insufficient evidence th time, which is important when treating a long-term condition.
Estonian: Samuti ei olnud piisavalt tõendeid, et toime aja jooksul püsiks, mis on pikaaegse häire ravimisel oluline.
English: EMEA/H/C/000572/WS/007 EMEA/H/C/000573/W
Estonian: EMEA/H/C/000552/WS/0076 EMEA/H/C/000572/WS/0076 EMEA/H/C/000573/WS/0076
English: the change to the authorisation is Eli Lilly.
Estonian: Müügiloa muutmist taotles ettevõte Eli Lilly.
English: Neurotransmitters are chemica cells to communicate with one another.
Estonian: Neurotransmitterid on keemilised ühendid, mis võimaldavad närvirakkudel omavahel suhelda.
English: The CHMP noted that the studies had not proven that duloxetine would provide a r the indication applied for.
Estonian: Inimravimite komitee märkis, et uuringud ei ole tõestanud duloksetiini kasulikkust taotletava näidustuse korral.
English: 21 July 2010 EMA/CHMP/580268/2011
Estonian: EMA/901723/2011
English: Ariclaim is used to treat pain due to diabetic peripheral neuropathy (damage extremities that can occur in patients with diabetes).
Estonian: Ariclaimi kasutatakse diabeetilisest perifeersest neuropaatiast (jäsemete närvide kahjustus, mis võib esineda diabeediga patsientidel) tingitud valu raviks.
English: In addition to their approved uses, the three medicines were expected to be used to treat moderate to severe chronic (long-term) somatic pain in patients not regularly taking NSAID pain killers (nonsteroidal anti-inflammatory drugs).
Estonian: Lisaks heakskiidetud kasutamisviisidele kavatseti kolme ravimit kasutada ka mõõduka kuni raske kroonilise (pikaajalise) somaatilise valu raviks patsientidel, kes ei võta regulaarselt NSAID-i tüüpi valuvaigisteid (mittesteroidsed põletikuvastased ravimid).
English: Somatic pain is from the body surfaces (such as skin) or
Estonian: Somaatiline valu pärineb keha pinnalt (näiteks nahk) või lihas-skeleti kudedest (näiteks skeletilihased, luud ja liigesed).
English: MP) adopted a negative opinion, recommending the refusal of a change to the marketing authorisations for the duloxetinecontaining medicines Ariclaim, Cymbalta and Xeristar.
Estonian: 21. juulil 2011 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades duloksetiini sisaldavate ravimite Ariclaimi, Cymbalta ja Xeristari müügilubade muutmisest keelduda.
English: The change concerned the addition of a new e chronic somatic pain in patients not taking NSAIDs regularly.
Estonian: Muudatuse põhjus oli uue näidustuse lisamine, milleks oli mõõduka kuni tugeva kroonilise somaatilise valu ravi patsientidel, kes ei võta regulaarselt mittesteroidseid põletikuvastaseid ravimeid.
English: What consequences does this refusal have for patients in clin compassionate use programm
Estonian: Kuidas mõjutab keeldumine praegu kliinilistes uuringutes või ravimi eriloaga kasutamise programmides osalevaid patsiente?
English: Since these neurotransmitters are i of pain, blocking their re-uptake into nerve cells may improve the symptoms of p
Estonian: Et need neurotransmitterid osalevad valuaistingu vähendamises, võib nende närvirakkudesse tagasihaarde pärssimine leevendada valusümptomeid.
English: The CHMP therefore concluded that the benefits of d chronic somatic pain in patients not regularly taking NSAIDs had not been and recommended that
Estonian: Seetõttu järeldas inimravimite komitee, et ei ole näidatud, et duloksetiini kasulikkus mõõduka kuni raske kroonilise somaatilise valu ravis patsientidel, kes ei võta regulaarselt mittesteroidseid põletikuvastaseid ravimeid, kaaluks üles ravimiga kaasnevad riskid.
English: Ariclaim, Cymbalta and Xeristar are medicines containin
Estonian: Ariclaim, Cymbalta ja Xeristar on ravimid, mis sisaldavat toimeainena duloksetiini.
English: Page 2/2
Estonian: 17. november 2011
English: It does not include pain from h and intestines.
Estonian: See ei hõlma siseorganitest (nt maost ja soolestikust) pärinevat valu.
English: The company informed the CHMP that there are currently no ongoing clinical t Cymb
Estonian: Ettevõte teatas inimravimite komiteele, et praegu ei ole Euroopas pooleli ühtegi Ariclaimi, Cymbalta ja Xeristari kliinilist uuringut kroonilise somaatilise valuga patsientidel.
English: ts of five main studies in 839 patients with chronic somatic pain: two studies in patients with knee pain caused by osteoarthritis (swelling and pain in the joints) and three in ne or placebo (a nts taking them in combination with NSAIDs.
Estonian: Kaks uuringut viidi läbi osteoartriidist (liigeste turse ja valu) tingitud põlvevaluga patsientidel ja kolm uuringut kroonilise alaseljavaluga patsientidel.
English: What were the CHMP's main concerns that led to the refusal to the
Estonian: Mis olid peamised probleemid, mille tõttu soovitas inimravimite komitee müügilubade muutmisest keelduda?
English: Patients in the studies were treated with duloxeti dummy treatment) with some patie effectiveness was the change in the severity of pain, as recorded by the patients after 12 or 13 weeks of treatment.
Estonian: Efektiivsuse põhinäitaja oli muutus valu tugevuses, mille patsient märkis üles 11-pallisel skaalal pärast 12 või 13 ravinädalat.
English: uloxetine in the treatment of moderate to severe shown to outweigh its risks the change to the marketing authorisations be refused.
Estonian: Kuid komitee järeldas, et neile probleemidele ei ole veel piisavalt tähelepanu pööratud, ja kinnitas oma esialgset negatiivset arvamust, soovitades müügilubade muutmisest keelduda.
English: By blocking their re-uptake, dul of these neurotransmitters in the spaces between these nerve cel communication between the cells.
Estonian: Nende tagasihaarde pärssimisega suurendab duloksetiin nende neurotransmitterite arvu närvirakkude vahel, suurendades rakkudevahelist infovahetust.
English: The main measure of on an 11-point scale of the change elevant benefit in at its effect could be maintained over nformation was n elderly patients and its safety in the intended patients including the elderly.
Estonian: Lisaks on vaja rohkem teavet duloksetiini toimete kohta eakatele patsientidele ja selle ohutuse kohta sihtrühma patsientidele, sealhulgas eakatele.
English: Refusal of a change to the marketing authorisation for Ariclaim, Cymbalta and Xeristar EMA/CHMP/580268/2011
Estonian: Ariclaimi, Cymbalta ja Xeristari (duloksetiin) müügilubade muutmisest keeldumine
English: It works by preventi the neurotransmitters 5-hydroxytrypamine (also called serotonin) and no back up into nerve cells in the brain and spinal cord.
Estonian: Toimeaine duloksetiin on serotoniini ja noradrenaliini tagasihaarde inhibiitor, mis pärsib neurotransmitterite 5hüdroksütrüptamiini (serotoniin) ning noradrenaliini tagasihaaret peaaju ja seljaaju närvirakkudesse.
English: The medicines are expected to work in the same way they do in diabetic periphera active substance duloxetine, is a serotonin-noradrenaline re-uptake inhibitor.
Estonian: Ravimite toime on eeldatavasti samasugune kui diabeetilise perifeerse neuropaatia korral.
English: The company presented resul patients with chronic low back pain.
Estonian: Ettevõte esitas viie peamise uuringu tulemused, milles osales 839 kroonilise somaatilise valuga patsienti.
English: 1 pre-filled syringe with needle safety guard
Estonian: Nõelakaitsega 0,7 ml (10000 RÜ/ml) 1 süstel intravenoosne kasutus süstel (klaas)
English: Γ.Α.Σταμάτης & Σια Λτδ.
Estonian: Κύπρος Γ.Α.Σταμάτης & Σια Λτδ.
English: 31 July 2021
Estonian: 31. juuli 2021
English: If you feel tired, do not drive or use machines until you feel better.
Estonian: Kui olete väsinud, ärge juhtige autot ega töötage masinatega enne, kui tunnete ennast paremini.
English: For the treatment to be fully effective, it is very important to keep having the infusions.
Estonian: Et ravi oleks igati tõhus, on väga tähtis infusioonidega jätkata.
English: SPECIAL STORAGE CONDITIONS Store in a refrigerator.
Estonian: SÄILITAMISE ERITINGIMUSED Hoida külmkapis
English: Overall, ADA status appeared to have no clinically relevant impact on safety.
Estonian: Üldiselt ei tundunud ADA staatusel olevat kliiniliselt olulist mõju ohutusele.
English: (neutropenia, leukopenia)
Estonian: (neutropeenia, leukopeenia);
English: The median age was 73 years.
Estonian: Vanuse mediaan oli 73 aastat.
English: Do not try to treat yourself with other medicines.
Estonian: Ärge püüdke ennast ise teiste ravimitega ravida.
English: Your doctor may:
Estonian: Teie arst võib:
English: Details on how to minimise the safety concerns through appropriate monitoring and management.
Estonian: Juhised ohutusega seotud asjaolude vähendamiseks asjakohase jälgimise ja tegevuse kaudu.
English: It is used when this cancer is advanced.
Estonian: Seda kasutatakse juhul, kui antud vähk on kaugelearenenud.
English: OTHER SPECIAL WARNING(S), IF NECESSARY Do not shake the vial
Estonian: TEISED ERIHOIATUSED (VAJADUSEL) Viaali ei tohi loksutada
English: Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.
Estonian: Teatage oma arstile või meditsiiniõele, kui te kasutate, olete hiljuti kasutanud või kavatsete kasutada mis tahes muid ravimeid.
English: Before your treatment, your doctor will check your general health.
Estonian: Enne ravi alustamist kontrollib arst teie üldist tervislikku seisundit.
English: They may happen weeks or months after your last dose.
Estonian: Need võivad ilmneda nädalaid või kuid pärast viimast annust.
English: For all subgroup analyses, formal statistical testing was not planned.
Estonian: Alarühma analüüside puhul ei kavandatud vormikohast statistilist testimist.
English: The safety and efficacy of Tecentriq in children and adolescents aged below 18 years have not been established.
Estonian: Tecentriq'u ohutus ja efektiivsus lastel ja noorukitel vanuses alla 18 aasta ei ole tõestatud.
English: The time to onset was 18 and 33 days.
Estonian: Algusaeg oli 18. ja 33. päev.
English: These results should be interpreted with caution due to the open-label design of the study.
Estonian: Neid tulemusi tuleb tõlgendada ettevaatusega uuringu avatud ülesehituse tõttu.
English: • Give you other medicines to prevent complications and reduce symptoms.
Estonian: • anda teile teisi ravimeid tüsistuste vältimiseks ja sümptomite leevendamiseks;
English: Nederland Roche Nederland B.V.
Estonian: Roche Nederland B.V.
English: A total of 931 patients were enrolled.
Estonian: Uuringusse kaasati kokku 931 patsienti.
English: In order to improve the traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded in the patient file.
Estonian: Et parandada bioloogiliste ravimpreparaatide kasutamise jälgitavust, tuleb manustatud preparaadi kaubanduslik nimetus ja partii number registreerida selgelt patsiendi kaarti.
English: • have an auto-immune disease (a condition where the body attacks its own cells)
Estonian: • teil on autoimmuunhaigus (haigus, mille puhul organism ründab oma enda rakke).